Dernières nouvelles pour D-Wave Quantum (NYSE:QBTS) Stock

D-Wave Quantum

D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.

D-Wave Quantum Inc

D-Wave Quantum Inc. Warrants, each whole warrant exercisable for 1.4541326 Common Shares at an exercise price of $11.50

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.35% to 40,369.59 while the NASDAQ fell 0.10% to 17,349.14. The S&amp;P 500 also fell, dropping, 0.03% to 5,527.22.
Check This Out: <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a>
Leading and Lagging Sectors Real estate shares jumped by 0.6% on Monday.
In trading on Monday, energy fell by 1.2%.
Top Headline
The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) reported better-than-expected earnings for its first quarter on Tuesday.
The company posted quarterly earnings of 73 cents per share which beat the analyst consensus estimate of 72 cents per share. The company reported quarterly sales of $11.10 billion which missed the analyst consensus estimate of $11.14 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares shot up 103% to $0.0262.</li>
<li>Shares of Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>)got a boost, surging 86% to $0.0070.</li>
<li>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares were also up, gaining 62% to $0.6686 after the company announced a pharmacy integration with Eli Lilly&#8217;s LillyDirect pharmacy provider, Gifthealth.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares dropped 77% to $0.1388.</li>
<li>Shares of Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) were down 55% to $0.0259.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) was down, falling 28% to $0.0965.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $60.79 while gold traded down 0.9% at $3,318.10.
Silver traded up 1.8% to $33.595 on Tuesday, while copper rose 0.3% to $4.9030.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.3%, Germany's DAX 40 gained 0.6% and France's CAC 40 fell 0.3%. Spain's IBEX 35 Index fell 0.8%, while London's FTSE 100 rose 0.4%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with China's Shanghai Composite falling 0.05%, Hong Kong's Hang Seng Index gaining 0.16% and India's BSE Sensex gaining 0.09%.
Economics
<ul>
<li>The number of job openings in the U.S. declined by 288,000 to 7.192 million in March, compared to market estimates of 7.48 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 4.5% year-over-year in February.</li>
<li>The FHFA house price index increased by 0.1% in February versus a revised 0.3% rise in January.</li>
<li>U.S. wholesale inventories climbed 0.5% month-over-month to $908 billion during March.</li>
<li>The U.S. trade deficit in goods increased to $162 billion in March compared to market estimates of a $146 billion gap.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45065334/amazon-com-to-253-here-are-10-top-analyst-forecasts-for-tuesday">Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AGMH

IXHL

LGMK

PTPI

US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $13.71 billion</a>, driven by double-digit growth in oncology and biopharmaceuticals.
The company&#8217;s adjusted EPADS&nbsp;reached&nbsp;$1.25, beating the consensus of $1.11. The adjusted EPS was $2.09 (1 ADR = 2 Common Shares).
AstraZeneca&#8217;s top business, oncology,&nbsp;<a href="https://www.astrazeneca.com/content/dam/az/PDF/2025/q1/Q1-2025-results-announcement.pdf" target="_blank" rel="noreferrer noopener">increased</a>&nbsp;10% (up 13% on constant currency) to $5.64 billion.
<ul>
<li>Tagrisso sales were up 5% to $1.68 billion (8% at CER), Imfinzi revenues were up 13% (+16%) to $1.26 billion, Calquence sales increased 6% to $762 million, Lynparza sales increased 3% (+8%) to $726 million, and Enhertu revenue was up 29% (39% at CER) to $596 million.</li>
<li>On Tuesday, The Committee for Medicinal Products for Human Use of the European Medicines Agency <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html" target="_blank" rel="noreferrer noopener">recommended</a> approving a fixed-duration regimen of Calquence&nbsp;in combination with venetoclax, with or without obinutuzumab, for adult patients with previously untreated chronic lymphocytic leukemia.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Cardiovascular, Renal, and Metabolism (CVRM) sales increased 8% (up 12% at CER) to&nbsp;$3.25 billion.
<ul>
<li>Farxiga sales were up 11% (16% at CER) to $2.06 billion.</li>
</ul>
Respiratory &amp; Immunology (R&amp;I) sales increased 11% (13% CER) to $2.08 billion.
<ul>
<li>Symbicort revenues fell 6% (-3% CER) to $723 million, and Fasenra sales increased 17% (+19%) to $418 million.</li>
</ul>
Rare Disease drug sales decreased by 3% to&nbsp;$2.04 billion.
<ul>
<li>Ultomiris sales were up 22% (25% at CER) to $1.05 billion, offset by a 40% decline in Soliris (38% at CER) to $444 million.</li>
</ul>
China: In relation to the illegal drug importation <a href="https://www.wsj.com/health/pharma/astrazeneca-sales-earnings-rise-warns-of-mounting-legal-challenges-in-china-718ddef7">allegations</a>, AstraZeneca received an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.6 million, referring to the Appraisal Opinion related to Enhertu.
<ul>
<li>A fine of between one and five times (up to $8 million) the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable.</li>
<li>China&#8217;s sales accounted for 13% of quarterly sales, which is up 3% on a reported basis to&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" target="_blank" rel="noreferrer noopener">$1.81 billion (+5% at CER)</a>.</li>
</ul>
AstraZeneca CEO Pascal Soriot said the company is &#8220;firmly committed to investing and growing in the U.S.&#8221; and continues to benefit from a &#8220;broad-based source of revenue and global manufacturing footprint.&#8221; 
AstraZeneca has 11 production sites in the U.S. covering small molecules, biologics as well as cell therapy. It also has two large R&amp;D sites in Gaithersburg MD and Cambridge MA.&#8221;
Guidance:&nbsp;For fiscal year 2025, AstraZeneca forecasts total revenue to increase by a high single-digit percentage and core EPS to increase by a low double-digit percentage.
On Tuesday, AstraZeneca <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html" rel="noreferrer noopener">announced</a> the discontinuation of its CAPItello-280 Phase 3 trial of Truqap&nbsp;(capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer.
The Independent Data Monitoring Committee reviewed and concluded that the&nbsp;Truqap&nbsp;combination was unlikely to meet the dual primary endpoints of radiographic progression-free survival and overall survival versus the comparator arm upon trial completion.
Price Action:&nbsp;AZN stock is down 0.13% at $69.84 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45051380/plaintiff-sues-eli-lilly-johnson-johnson-over-alleged-breast-cancer-risk-linked-to-antipsychotic-medications" target="_blank" rel="noreferrer noopener">Plaintiff Sues Eli Lilly, Johnson &amp; Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Guidance

Health Care

Movers

General

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

New Plan Latest Addition to Company's Comprehensive Benefits, Including Minimum $20 Starting Wage, Market-Leading Retirement Contributions and Tuition-Free Education
STAMFORD, Conn., April 29, 2025 /PRNewswire/ --&nbsp;Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) today announced the launch of an Employee Stock Purchase Plan (ESPP), designed to encourage and reward employee tenure and empower its workforce to share in the Company's success. Eligible employees will now have the opportunity to purchase Charter stock through payroll deductions and will receive matching Restricted Stock Units (RSUs) based on their years with Charter.

CHTR

Charter Communications Launches ESPP, Offering Employees Stock Purchase And Tenure-Based RSUs

Raymond James analyst Patrick Tyler Brown maintains Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Outperform and lowers the price target from $300 to $295.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Vulcan Materials, Lowers Price Target to $295

Raymond James analyst Patrick Tyler Brown maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Outperform and lowers the price target from $600 to $597.

Raymond James Maintains Outperform on Martin Marietta Materials, Lowers Price Target to $597

Raymond James analyst Patrick Tyler Brown maintains Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) with a Strong Buy and lowers the price target from $104 to $100.

ROAD

Raymond James Maintains Strong Buy on Construction Partners, Lowers Price Target to $100

Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) has outperformed the market over the past 5 years by 2.13% on an annualized basis producing an average annual return of 16.3%. Currently, Kinross Gold has a market capitalization of $17.94 billion. 
Buying $100 In KGC: If an investor had bought $100 of KGC stock 5 years ago, it would be worth $213.08 today based on a price of $14.58 for KGC at the time of writing.
<h3>Kinross Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745936112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

FitVine Wine becomes official wine sponsor of Life Time Pickleball, bringing delicious zero-sugar wine to more than 775 courts across the U.S.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fitvinewine.com%2F&amp;esheet=54245288&amp;newsitemid=20250429419535&amp;lan=en-US&amp;anchor=FitVine+Wine&amp;index=1&amp;md5=b149c0cdc8bf94d2d6c142ce9c60a8cf">FitVine Wine</a>, a leading wellness wine brand, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lifetime.life%2F&amp;esheet=54245288&amp;newsitemid=20250429419535&amp;lan=en-US&amp;anchor=Life+Time&amp;index=2&amp;md5=dec070fb7e9a8dce6810e8784a7eea26">Life Time</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>), the nation's premier healthy lifestyle brand, today announced an exciting new agreement designed to bring mindful indulgence to Life Time members nationwide. As the official wine sponsor of Life Time Pickleball, FitVine will be integrated into a variety of premium social and wellness experiences in clubs across the country, including select Life Time Pickleball Classic tournaments and Afterglo events.

Fitvine Wine And Life Time Announce New Agreement To Bring Mindful Indulgence To Life Time Members Nationwide

WIIM

RCL stock has given up its prior gain. Royal Caribbean shares were trading higher after the company raised its FY25 adjusted EPS guidance.

<ul>
<li>Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.</li>
<li>High transgene expression and improved safety profile of Aldveron's Nanoplasmid&#x2122;&nbsp;vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx&#x2122; platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.</li>
<li>A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in New Orleans.</li>
</ul>
CAMBRIDGE, Mass. and FARGO, N.D., April 29, 2025 /PRNewswire/ --&nbsp;Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced,&nbsp;a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid&#x2122; vector technology with Kytopen's Flowfect Tx&#x2122; GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.

Kytopen And Aldevron Announce Joint Marketing Agreement To Enhance Workflow Solutions For Cell Therapy Manufacturers

Raymond James analyst Savanthi Syth reiterates Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Outperform and lowers the price target from $42 to $40.

Reiteration

Raymond James Reiterates Outperform on Southwest Airlines, Lowers Price Target to $40

Eagle Bancorp Montana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBMT#NASDAQ">EBMT</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.32 by 28.12 percent. This is a 70.83 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $20.92 million which beat the analyst consensus estimate of $16.64 million by 25.74 percent. This is a 37.49 percent increase over sales of $15.21 million the same period last year.

Earnings Beats

EBMT

Eagle Bancorp Montana Q1 EPS $0.41 Beats $0.32 Estimate, Sales $20.92M Beat $16.64M Estimate

Raymond James analyst Ric Prentiss reiterates SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Strong Buy and raises the price target from $265 to $268.

SBAC

Raymond James Reiterates Strong Buy on SBA Communications, Raises Price Target to $268

<a href="https://www.paloaltonetworks.com/content/pan/en_US/company/press/2025/at-t-joins-forces-with-palo-alto-networks-to-introduce-secure-connectivity-solution-for-business-customers.html">https://www.paloaltonetworks.com/content/pan/en_US/company/press/2025/at-t-joins-forces-with-palo-alto-networks-to-introduce-secure-connectivity-solution-for-business-customers.html</a>

PANW

AT&T Joins Forces with Palo Alto Networks to Introduce Secure Connectivity Solution for Business Customers

Raymond James analyst Andrew Cooper reiterates Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Outperform and lowers the price target from $145 to $120.

RVTY

Raymond James Reiterates Outperform on Revvity, Lowers Price Target to $120

AFMD

Affimed Demonstrates Increased AFM24 Exposure Correlates With Improved Response Rates And Progression-Free Survival In Refractory NSCLC Patients At AACR Annual Meeting

Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) shares are trading higher after the company <a href="https://www.benzinga.com/pressreleases/25/04/b45062667/corning-announces-strong-first-quarter-2025-financial-results-1-and-reiterates-confidence-in-sprin" target="_blank" rel="noreferrer noopener">reported first-quarter 2025 results</a>.
Core sales grew&nbsp;13%&nbsp;year-on-year (Y/Y) to&nbsp;$3.68 billion, beating the&nbsp;analyst <a href="https://www.benzinga.com/earnings">consensus estimate of&nbsp;$3.64 billion</a>.&nbsp;
The Apple glass supplier's core EPS of 54 cents beat the analyst consensus estimate of 51 cents.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45039357/apples-india-game-plan-looks-smarter-as-tariff-heat-rises-analyst-highlights-4-stocks-that-could-benefit" rel="noreferrer noopener">Apple&#8217;s India Game Plan Looks Smarter As Tariff Heat Rises &#8211; Analyst Highlights 4 Stocks That Could Benefit</a>
As of January 1, 2025, Honeywell reorganized its business segments, moving the Automotive Glass Solutions business from the Hemlock and Emerging Growth Businesses into the newly formed Automotive segment, where it is now managed alongside Environmental Technologies.
Display Technologies' sales grew by&nbsp;4% Y/Y&nbsp;to&nbsp;$905&nbsp;million.&nbsp;Optical Communications sales increased by&nbsp;46% Y/Y&nbsp;to&nbsp;$1.355 billion,&nbsp;led by continued strong adoption of Corning's new Gen AI products.
In Optical Communications, Enterprise business sales rose 106% Y/Y, led by strong demand for the new Gen AI products.
Specialty Materials sales rose&nbsp;10% Y/Y&nbsp;to&nbsp;$501&nbsp;million in the quarter. Life Sciences sales fell&nbsp;1% Y/Y&nbsp;to&nbsp;$234 million.
Hemlock and Emerging Growth Businesses sales decreased&nbsp;11% Y/Y to&nbsp;$244 million in the quarter.
The core gross margin was&nbsp;37.9% in the quarter, an improvement of 110-basis-point year-over-year.
Outlook: In the second quarter, the company expects to grow core sales to around $3.85 billion (vs. the consensus of $3.82 billion) and increase core EPS significantly faster than sales, in a range of $0.55-$0.59<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noopener"> (vs. the </a><a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">street view of $0.56)</a>.
The guidance reflects the impact of currently enacted tariffs of around $0.01-$0.02, along with a $0.03 temporary increase in cost to meet increased demand for Gen AI and solar products.
Wendell P. Weeks, chairman and chief executive officer, said,&nbsp;&#8220;We remain confident in our ability to deliver our&nbsp;Springboard plan. We&#8217;re well positioned to maintain momentum despite a dynamic external environment because our growth is underpinned by powerful secular trends that are underway today.&#8221;
Investors can gain exposure to GLW via ProShares Smart Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TINT#NYSE">TINT</a>) and Professionally Managed Portfolios Otter Creek Focus Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFS#NYSE">OCFS</a>).
Price Action: GLW shares were up 1.70% at $44.85 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44950358" target="_blank" rel="noreferrer noopener">Amphenol Q1 Earnings: 48% Topline Growth, Driven By IT, Mobile, Defense Sectors</a></li>
</ul>
Photo: Shutterstock

Professionally Managed Portfolios Otter Creek Focus Strategy ETF

OCFS

TINT

Gen AI Demand Ignites Corning Q1 Optical Communications Sales, Sees Continued Growth In Q2 Despite Tariff Woes

Raymond James analyst Daniel Tamayo reiterates Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) with a Outperform and lowers the price target from $45 to $41.

MBIN

Raymond James Reiterates Outperform on Merchants Bancorp, Lowers Price Target to $41

<a href="https://www.reuters.com/business/energy/china-waives-tariffs-us-ethane-imports-sources-say-2025-04-29/">https://www.reuters.com/business/energy/china-waives-tariffs-us-ethane-imports-sources-say-2025-04-29/</a>

'China waives tariffs on US ethane imports, sources say'- Reuters

Raymond James analyst Buck Horne maintains M/I Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHO#NYSE">MHO</a>) with a Strong Buy and lowers the price target from $168 to $140.

Comments

D-Wave Quantum

Actualités

Dernières nouvelles pour D-Wave Quantum (NYSE:QBTS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL